deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT02477696

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Sponsor: Acerta Pharma BV

Updated 28 times since 2017 Last updated: Nov 13, 2025 Started: Jul 28, 2015 Primary completion: Sep 15, 2020 Completion: Jan 3, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02477696, this PHASE3 trial focuses on Chronic Lymphocytic Leukemia and remains ongoing. Sponsored by Acerta Pharma BV, it has been updated 28 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jan 2018 · 7 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Aug 2023 · 4 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Jul 2025 · 4 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

28 versions recorded
  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE3

Show 23 earlier versions
  1. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

  7. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  11. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  13. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  14. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  15. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  16. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  17. Jan 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  18. May 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE3

  19. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  20. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  21. Jun 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  22. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  23. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acerta Pharma BV
Data source: Acerta Pharma BV

For direct contact, visit the study record on ClinicalTrials.gov .